Blackstone Emerges As Likely Buyer For Takeda's OTC Business At Price Close To $3Bn
Executive Summary
Takeda's divestment long has been rumored and would take it to its oft-stated target of selling around $10bn in assets to pay down debt associated with its $62bn purchase of Shire that closed in January 2019.
You may also be interested in...
Nidda Investment Group Takes Full Ownership Of Stada Through Settlements With Shareholders
Nidda Healthcare, investment vehicle controlled by Bain Capital and Cinven, secured a “timely” squeeze-out of minority shareholders in Stada through settlement terms that include a one-time payment of 10 euro cents per outstanding share for the remaining shareholders.
Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties
Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.
Ferring And Blackstone Launch Gene Therapy Company
The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.